Table 3.

Phase 3 trials of ixazomib in MM

Study	NCT number	Regimen(s)	Patients	1° endpoint	Status
C160106	NCT01564537	Ixazomib-Rd vs placebo-Rd	Relapsed and/or refractory, 1–3 prior therapies	PFS	Ongoing
C16014	NCT01850524	Ixazomib-Rd vs placebo-Rd	Newly diagnosed ASCT-ineligible	PFS	Ongoing
C16019	NCT02181413	Ixazomib vs placebo	Newly diagnosed, with response to induction therapy followed by ASCT	PFS	Ongoing
C16021	NCT02312258	Ixazomib vs placebo	Newly diagnosed, with response to induction therapy but have not undergone ASCT	PFS	Recruiting

Abbreviations: ASCT, autologous stem cell transplant; MM, multiple myeloma; PFS, progression-free survival; Rd, lenalidomide-dexamethasone.